Analystreport

Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $7.00 to $6.00. They now have a "buy" rating on

Oncolytics Biotech Inc. - Common Shares  (ONCY) 
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.oncolyticsbiotech.com